# Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine

> **NCT05110417** · PHASE4 · UNKNOWN · sponsor: **Eastern Virginia Medical School** · enrollment: 10 (estimated)

## Conditions studied

- Dysphonia, Spastic
- Dysphonia
- Laryngeal Dystonia

## Interventions

- **DRUG:** Pyridostigmine Bromide 60 Milligrams (mg)

## Key facts

- **NCT ID:** NCT05110417
- **Lead sponsor:** Eastern Virginia Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-20
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110417, "Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05110417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*